GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Operating Margin %

Invex Therapeutics (ASX:IXC) Operating Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Invex Therapeutics's Operating Income for the six months ended in Dec. 2024 was A$-0.47 Mil. Invex Therapeutics's Revenue for the six months ended in Dec. 2024 was A$0.00 Mil. Therefore, Invex Therapeutics's Operating Margin % for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Invex Therapeutics's Operating Margin % or its related term are showing as below:


ASX:IXC's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -117.725
* Ranked among companies with meaningful Operating Margin % only.

Invex Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Invex Therapeutics's Operating Income for the six months ended in Dec. 2024 was A$-0.47 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was A$-1.33 Mil.


Invex Therapeutics Operating Margin % Historical Data

The historical data trend for Invex Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Operating Margin % Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
Operating Margin %
- - - - -

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Invex Therapeutics's Operating Margin %

For the Biotechnology subindustry, Invex Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invex Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Operating Margin % falls into.


;
;

Invex Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Invex Therapeutics's Operating Margin % for the fiscal year that ended in Jun. 2024 is calculated as

Operating Margin %=Operating Income (A: Jun. 2024 ) / Revenue (A: Jun. 2024 )
=-3.348 / 0
= %

Invex Therapeutics's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=-0.472 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invex Therapeutics  (ASX:IXC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Invex Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Invex Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.

Invex Therapeutics Headlines

From GuruFocus

Ken Fisher's Top 4th-Quarter Trades

By Graham Griffin Graham Griffin 02-01-2021

Fisher Asset Management Trims Infosys, Equinor Positions

By Tiziano Frateschi Tiziano Frateschi 02-07-2021

Verger Capital Management LLC Buys iShares Global Energy ETF, iShares Gold Trust

By GuruFocus Research GuruFocus Editor 10-29-2021